Research Compound
Retatrutide
Volume pricing Auto-applied at checkout. The more you order, the more you save.
- Get it Jun 4–Jun 10 · ships in 1-2 business days
- Free shipping on orders $150+
- Independent COA available, email support@aeternumlabs.co after ordering
A triple incretin receptor agonist (GLP-1 / GIP / glucagon) in active clinical investigation — among the most potent metabolic research compounds available, studied for weight reduction, glucose homeostasis, and cardiometabolic improvement.
Research LibraryRead the full Retatrutide research guide for mechanism, dosing windows, half-life, citations, and stack pairings.
For research use only. Not intended for human or animal consumption. In vitro research purposes only.
Every batch is third-party tested for purity and potency. If your product arrives damaged or doesn't meet our standards, we'll replace it, no questions asked.
The Aeternum difference
Why researchers choose us over cheaper vendors.
Quick answers
Common questions
When does my batch COA arrive?
How does this ship?
How long does this store?
What is your refund policy?
Is this approved for human or animal use?
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide that simultaneously agonizes three incretin and metabolic hormone receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). This tri-agonist profile distinguishes it from dual agonists such as tirzepatide and from pure GLP-1 agonists, creating a uniquely potent metabolic compound targeting appetite regulation, insulin secretion, hepatic glucose output, and energy expenditure simultaneously.
Research Context
Phase 2 clinical data have positioned Retatrutide among the most potent weight-reducing agents yet studied, with reported average body weight reductions of approximately 24% over 48 weeks. Mechanistically, GLP-1R agonism reduces appetite and gastric emptying, GIPR agonism contributes additional insulinotropic and adipocyte effects, and GCGR agonism drives hepatic glucose output reduction and increased energy expenditure. Preclinical cardiovascular and metabolic studies have explored effects on triglycerides, NASH/NAFLD endpoints, and cardiometabolic biomarkers.
Research Applications
- Triple incretin receptor pharmacology and selectivity
- Obesity and energy homeostasis research
- Glucose metabolism, insulin sensitivity, and beta-cell function
- NAFLD / NASH and hepatic lipid metabolism models
- Cardiometabolic risk factor research
For research use only. Not for human or animal consumption.
This compound's precise mechanism continues to be characterized through ongoing preclinical research. Investigators have proposed interactions with growth factor signaling pathways, receptor modulation, and cellular repair cascades. Consult current peer-reviewed literature for the most up-to-date mechanistic hypotheses.
Store lyophilized powder at −20°C for up to 24 months. Once reconstituted with bacteriostatic water, store at 4°C and use within 28 days. Protect from light, moisture, and repeated freeze-thaw cycles. Handle in a clean laboratory environment with appropriate PPE. For research use only, not for human or animal administration.
Use our Peptide Reconstitution Calculator to determine the exact volume of bacteriostatic water to add. Allow the solvent to run down the inside of the vial slowly, do not inject directly onto the lyophilized cake. Swirl gently; do not shake. The solution should appear clear to slightly opalescent.
Orders ship in discreet, unmarked packaging with no reference to Aeternum Labs on the exterior. All shipments include full tracking and are insured against loss or damage. Most orders are dispatched within 1 to 2 business days. Cold-chain packaging is included where required to maintain compound integrity during transit.
Research Grade Quality
Built for the Lab
Every vial is third-party tested for identity, purity, and potency before it leaves our facility. Documentation included with every order.
